Treatment with either molecule induces blocking in the G1 phase of the cell cycle in both cell lines: NSCLC-N6-L16, which has a mutated TP53, and A549, which has a wild type TP53. As overexpression of TP53 was only seen in NSCLC-N6-L16, it seems likely that the blocking in G1 and the apoptosis brought about by both pro-apoptotic treatments do not occur by the same signaling pathway. The gene discussed is TP53; the disease is non-small cell lung carcinoma.